CAMBRIDGE, Mass., Sept. 12 /PRNewswire/ -- Genstruct Inc., a biotechnology company translating the complexity of human biology to develop new successful therapeutics, announced today that its president and CEO, Dr. Keith O. Elliston, has been invited to speak at the Oncology Clinical Trial Summit in Arlington, Va., September 17-18.
Dr. Elliston will participate in a panel discussion focused on "Enhancing Development and Commercial Value Added in Care Delivery and Medicines by Leveraging and Integrating Innovative, Intelligent Technology Platforms." The panel will be moderated by Angeliki Kotsianti, M.D., Ph.D., director, Global Clinical Technology for Pfizer Human Health Technologies and be held on September 17 at 3:30 p.m.
"We understand the challenges of oncology clinical trials and have been focused on developing new approaches with our partnering pharmaceutical companies to deliver actionable hypotheses and mechanistic biomarkers for oncology drug development," said Dr. Keith O. Elliston, president and CEO at Genstruct. "Participating in this panel is a great opportunity to share our causal modeling methodology for translating research results into successful oncology clinical trials and to further improve healthcare delivery to cancer patients."
Dr. Elliston is an invited speaker at many biotechnology and
pharmaceutical industry events. He is an experienced entrepreneur and
intrapreneur who has dedicated his career to the development of
leading-edge technology for drug discovery and drug development. Dr.
Elliston spent over 10 years with Merck Research Laboratories, where he
served as the Director of Bioinformatics, and the scientific director of
the Merck Gene Index project. He then joined Bayer Pharmaceuticals where he
founded their global genomics and bioinformatics efforts, and was the
section head of Genomics and the worldwide head of Bioinformatics. In 1997
Dr. Elliston joined Gene Logic as Chief Scientific Officer and pioneered
|SOURCE Genstruct, Inc.|
Copyright©2007 PR Newswire.
All rights reserved